-
Traditional PBMs shroud their compensation and drug costs.
February 1Capital RX -
Unlike private health insurance, Part D drug plans have no cap on patients’ 5% coinsurance costs once they hit $6,550 in drug spending, which forces patients to rely on financial assistance programs. These arrangements, however, do nothing to reduce drug prices.
January 5 -
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs.
November 19 -
A coalition of employers is on a crusade to cut company spending on drugs nationwide by simply noting the cheaper choices already available, drawing the ire of drugmakers.
September 14 -
With prescription drug spending in the U.S. hitting $335 billion in 2018 and prescription drugs expected to be the fastest growing health category over the next 10 years, any action aimed at lowering drug prices should be applauded. However, time will tell if the President’s actions will pay off as intended.
August 24RxBenefits -
Drugs used to treat chronic conditions are being tried on coronavirus patients; CVS wants to ensure there’s enough to go around.
April 3 -
The healthcare company’s PBM designed a plan to ensure diabetics have access to medication without increasing employer costs.
January 29 -
The consulting firm partnered with an analytic company to help employers monitor the costs of specialty medications and opioid use in their health plans.
January 22 -
As medication costs continue to rise, employers should implement these strategies to mitigate the financial burden of pharmaceutical prices.
January 14 -
A state-run generic drug program would allow buyers to pool their bargaining power.
January 9